Quidel (NASDAQ:QDEL) will be releasing its earnings data after the market closes on Tuesday, November 6th. Analysts expect Quidel to post earnings of $0.40 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Quidel (NASDAQ:QDEL) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.12. The company had revenue of $103.16 million during the quarter, compared to analysts’ expectations of $102.15 million. Quidel had a net margin of 4.63% and a return on equity of 19.39%. On average, analysts expect Quidel to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of QDEL opened at $66.68 on Monday. Quidel has a twelve month low of $33.01 and a twelve month high of $77.63. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.10 and a quick ratio of 0.71. The company has a market cap of $2.60 billion, a PE ratio of -952.57, a price-to-earnings-growth ratio of 1.04 and a beta of 1.05.
QDEL has been the subject of several analyst reports. TheStreet cut shares of Quidel from a “b” rating to a “c+” rating in a research note on Wednesday, August 8th. Canaccord Genuity raised their target price on shares of Quidel from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, September 10th. Zacks Investment Research cut shares of Quidel from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 10th. BidaskClub raised shares of Quidel from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 5th. Finally, Barclays raised their target price on shares of Quidel from $65.00 to $78.00 and gave the company an “overweight” rating in a research note on Monday, August 6th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $74.86.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus products point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.